Importantly, 4SC‐202 but not the FDA‐approved inhibitor vismodegib, efficiently abrogated HH/GLI signaling in SUFU‐depleted human medulloblastoma cells resistant to SMOi‐therapy. This evidence concerns the gene GLI1 and medulloblastoma.